The report titled “Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020)” provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.

The report analyses the global Lynparza market in detail along with the regional analysis as it is the only commercialized product in the market. The clinical trials of Niraparib, Rucaparib, Talazoparib and Veliparib are also summarized along with the anticipated market commencement for each of the products.

The report provides detailed market potential of PARP inhibitor in Ovarian cancer, Breast cancer, Prostate cancer and Pancreatic cancer. This section provides the detailed analysis of the clinical trials of various PARP inhibitors for the concerned cancer treatment.

Growth of the overall global PARP inhibitor market has also been forecasted for the period 2016-2020, taking into consideration the research & development, the growth drivers and the current and future trends. The competition in the global PARP inhibitor market is stiff and dominated by the big players like AstraZeneca. Further, key players in the market, AbbVie, Clovis Oncology, Medivation and Tesaro are also profiled with their financial information and respective business strategies.

Regional Coverage

Global

Company Coverage

AstraZeneca PLC
AbbVie Inc.
Clovis Oncology, Inc.
Medivation, Inc.
Tesaro, Inc. 

Executive Summary


The global PARP inhibitor market has flourished since 2015 as in late 2014, the first PARP inhibitor product was launched and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The market is spread across the globe with the United States and Europe dominating the market.

The PARP inhibitor market can be segmented on the basis of the products into Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib. Currently, Lynparza is the only commercialized product in the market while other four products are in the development/trial stage. The market for Veliparib is expected to flourish since 2017 while the markets for Niraparib, Rucaparib and Talazoparib is expected to commence from 2018.

The major growth drivers for the global PARP inhibitor market are: rise in cancer incidences and PARP inhibitors in clinical routine. Despite the market is governed by growth drivers, there are certain challenges faced by the market such as: side-effects of PARP inhibitors and resistance to PARP inhibition. Some of the recent and major trends in the market include, various PARP inhibitors in the pipeline, inhibiting enzyme versus PARP trapping, the combination of PARP inhibitor & c-MET and pill burden likely to decline in the near future.

List of Figures:

Figure 1: Role of PARP Inhibitor
Figure 2: Global PARP Inhibitor Market by Value; 2015-2020E (US$ Million)
Figure 3: Global Lynparza Market by Value; 2015-2020E (US$ Million)
Figure 4: Global Lynparza Market by Region; 2015 (%)
Figure 5: Global Niraparib Market by Value; 2018E-2020E (US$ Million)
Figure 6: Global Rucaparib Market by Value; 2018E-2020E (US$ Million)
Figure 7: Global Talazoparib Market by Value; 2018E-2020E (US$ Million)
Figure 8: Global Veliparib Market by Value; 2017E-2020E (US$ Million)
Figure 9: Global Cancer Incidences; 2012-2020E (Million)
Figure 10: Global Cancer Cases by Types of Cancer; 2012 (%)
Figure 11: PARP Inhibitor Side-Effects Profile
Figure 12: AstraZeneca Total Revenue; 2011-2015 (US$ Billion)
Figure 13: AstraZeneca Total Revenue by Product Segments; 2015 (US$ Million)
Figure 14: AstraZeneca Total Revenue of Products by Region; 2015 (%)
Figure 15: AbbVie Total Revenue; 2011-2015 (US$ Billion)
Figure 16: AbbVie Total Revenue by Products; 2015 (%)
Figure 17: AbbVie Total Revenue by Region; 2015 (%)
Figure 18: Clovis Research & Development Expenditure; 2011-2015 (US$ Million)
Figure 19: Clovis Research & Development Expenditure by Products; 2015 (%)
Table 16: Clovis Oncology Company Product Development Pipeline
Figure 20: Medivation Collaboration Revenue; 2011-2015 (US$ Million)
Figure 21: Medivation Research & Development Expenditure; 2011-2015 (US$ Million)
Figure 22: Medivation Research & Development Expenditure by Products; 2015 (%)
Figure 23: Tesaro Research & Development Expenditure; 2011-2015 (US$ Million)
Figure 24: Tesaro Research & Development Expenditure by Products; 2015 (%)
Table 1: DDR Drug Portfolio
Table 2: PARP Inhibitors in Development
Table 3: Ongoing Phase III and Phase II Lynparza Trials
Table 4: Ongoing Niraparib Trials
Table 5: Ongoing Phase III and Phase II Rucaparib Trials
Table 6: Ongoing Talazoparib Trials
Table 7: Ongoing Phase III and Phase II Veliparib Trials
Table 8: Global PARP Inhibitor Market Potential
Table 9: Phase III Ovarian Cancer Trials
Table 10: Phase III Breast Cancer Trials
Table 11: Prostate Cancer Trials
Table 12: Pancreatic Cancer Trials
Table 13: Enzyme Inhibition and PARP Trapping Capabilities of Each PARP
Table 14: Global PARP Inhibitor Major Companies Ongoing Phase III Trial
Table 15: AstraZeneca Major Products


For further details, kindly visit :
http://www.daedal-research.com//global-parp-inhibitor-market-size-trends-and-forecasts-2016-2020

Rajeev Kumar
(Business Development Manager)
Address: 36 SFS Flats
Paschim Vihar
New Delhi-110063
Mobile: +91-9811715635
Tel: +91-120-4553017
Mail ID - [email protected]

Daedal Research is a research and consulting firm specialized in providing research reports and customized business research and analysis. For more Information:
http://www.daedal-research.com